Medicine Information

Motilon

Name: Motilon
Brand: Motilon
Rating: 4.5 (117 reviews)

Pediatric Drop1 mg/mlAnti-emetic & ProkineticATC: A03FA03

Generic Name

Domperidone

Manufacturer

Square Pharmaceuticals Ltd.

Country

Bangladesh

Loading images...

Price Details

Current market pricing information

Variant	Unit Price	Strip Price
motilon 1 mg pediatric drop	৳ 9.80	N/A

Description

Overview of the medicine

Motilon 1 mg Pediatric Drop contains Domperidone, an antiemetic and prokinetic agent used to treat nausea, vomiting, and certain gastrointestinal motility disorders in children. It works by blocking dopamine receptors.

Uses & Indications

Nausea and vomiting of various origins (post-chemotherapy, post-radiotherapy, functional dyspepsia)

Symptoms of dyspepsia (epigastric fullness, early satiety, abdominal distension, upper abdominal pain)

Gastro-oesophageal reflux disease (GERD) in children

Dosage

Adults

Not typically used as a primary formulation for adults; consult physician for appropriate adult formulations and dosage.

Elderly

Use with caution and at the lowest effective dose due to potential cardiac risks. Not the primary formulation.

Renal_impairment

Dosage reduction may be necessary in severe renal impairment. Consult a physician. Not the primary formulation.

How to Take

Administer orally using the calibrated dropper provided, preferably 15-30 minutes before meals. Do not exceed the prescribed dose or duration.

Mechanism of Action

Domperidone acts as a peripheral dopamine D2 receptor antagonist, primarily in the chemoreceptor trigger zone (CTZ) and the gastrointestinal tract. This action increases gastrointestinal motility and blocks the emetic response.

Pharmacokinetics

Onset

30-60 minutes

Excretion

Approximately 66% excreted in feces and 33% in urine as inactive metabolites.

Half life

7-9 hours (prolonged in severe renal impairment)

Absorption

Rapidly absorbed after oral administration; low absolute bioavailability (approx. 15%) due to extensive first-pass metabolism.

Metabolism

Extensively metabolized in the liver via CYP3A4.

Side Effects

Contraindications

Hypersensitivity to Domperidone or any component of the formulation.
Prolactin-releasing pituitary tumor (prolactinoma).
Moderate to severe hepatic impairment.
Conditions where increased gastrointestinal motility could be harmful (e.g., gastrointestinal hemorrhage, mechanical obstruction, perforation).
Known existing prolongation of cardiac conduction intervals (e.g., QT interval).
Significant electrolyte disturbances (hypokalemia, hypomagnesemia).
Concomitant use with potent CYP3A4 inhibitors (e.g., ketoconazole, erythromycin, clarithromycin, fluconazole, amiodarone, diltiazem, verapamil).
Concomitant use with other QT-prolonging drugs.

Drug Interactions

Antacids, H2-receptor antagonists (e.g., Cimetidine, Ranitidine)

May decrease the oral bioavailability of domperidone. Should not be taken simultaneously; administer domperidone before meals and antacids/H2-blockers after meals.

Potent CYP3A4 Inhibitors (e.g., Ketoconazole, Erythromycin, Clarithromycin)

Significantly increases plasma levels of domperidone, increasing the risk of QT prolongation. Concomitant use is contraindicated.

Other QT-prolonging drugs (e.g., some antiarrhythmics, antipsychotics, antidepressants)

Additive effect on QT interval, increasing the risk of arrhythmias. Concomitant use is contraindicated.

Storage

Store below 30°C in a dry place, away from light. Keep out of reach of children.

Overdose

Symptoms of overdose may include drowsiness, disorientation, extrapyramidal reactions, and possibly cardiac arrhythmias. Treatment is symptomatic and supportive, including gastric lavage and activated charcoal. ECG monitoring is recommended.

Pregnancy & Lactation

Limited data on use in pregnancy; should be used only if potential benefits justify the potential risk to the fetus. Domperidone is excreted in breast milk and may affect the infant; avoid during breastfeeding if possible or consider alternative treatment.

Frequently Asked Questions

Common questions about this medicine

Pack Sizes

15 ml bottle30 ml bottle

Shelf Life

24 to 36 months from manufacturing date.

Availability

Available in all pharmacies

Approval Status

Approved by DGDA (Bangladesh)

Patent Status

Off-patent

WHO Essential Medicine

Yes

Clinical Trials

Numerous clinical trials have established the efficacy and safety of Domperidone for gastrointestinal motility disorders and antiemetic effects, though recent focus includes cardiac safety.

Lab Monitoring

ECG monitoring should be considered in patients at risk of cardiac arrhythmias.
Renal function monitoring in patients with renal impairment.

Doctor Notes

Emphasize the importance of accurate dosing, especially in pediatric patients, to minimize risks.
Counsel parents/guardians about the cardiac risks associated with Domperidone and the need to strictly adhere to the prescribed dose and duration (max 7 days).
Avoid concomitant use with potent CYP3A4 inhibitors and other QT-prolonging drugs. Review patient's full medication list.
Consider ECG in patients with pre-existing cardiac conditions or those at higher risk.

Patient Guidelines

Administer the drops with the provided calibrated dropper for accurate dosing.
Take the medicine 15-30 minutes before meals for best results.
Do not exceed the prescribed dose or duration of treatment (usually not more than 7 days).
Consult a doctor if symptoms do not improve or worsen.
Be aware of potential cardiac risks and report any signs of heart problems (e.g., palpitations, fainting) to your doctor immediately.

Missed Dose Advice

If a dose is missed, take it as soon as you remember. If it is almost time for the next dose, skip the missed dose and resume your regular dosing schedule. Do not double the dose.